Viatris Inc. (VTRS)
| Market Cap | 11.52B |
| Revenue (ttm) | 15.47B |
| Net Income (ttm) | 1.83B |
| Shares Out | 1.20B |
| EPS (ttm) | 1.51 |
| PE Ratio | 6.36 |
| Forward PE | 3.40 |
| Dividend | $0.48 (5.00%) |
| Ex-Dividend Date | Nov 22, 2023 |
| Volume | 9,289,995 |
| Open | 9.61 |
| Previous Close | 9.68 |
| Day's Range | 9.53 - 9.65 |
| 52-Week Range | 8.74 - 12.40 |
| Beta | 1.14 |
| Analysts | Hold |
| Price Target | 12.00 (+24.87%) |
| Earnings Date | Nov 7, 2023 |
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $12.0, which is an increase of 24.87% from the latest price.
News
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars...
Why the Cheapest Stock in the S&P 500 Is No Bargain
Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed.
Viatris to Participate in the Jefferies London Healthcare Conference
PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in Londo...
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: ...
Viatris core profit beats on generic drugs strength
Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
Reports Total Revenues of $3.94 Billion; U.S. GAAP Net Earnings of $332 Million; Adjusted EBITDA of $1.36 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $834 Million; and Free Cash Fl...
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
PITTSBURGH , Oct. 30, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today it is hosting The Power of Partnership to Address Antimicrobial Resistance (AMR), a...
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
PITTSBURGH , Oct. 23, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023. Viatris has ...
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
PITTSBURGH , Oct. 20, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company ...
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
PITTSBURGH , Oct. 18, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it has been named to 3BL's annual 100 Best Corporate Citizens ranking, recognizing ...
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
PITTSBURGH , Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets. C...
Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
LONDON--(BUSINESS WIRE)--Theramex, a leading global speciality pharmaceutical company dedicated to women's health, is pleased to announce that it has entered into an agreement to acquire the European ...
Drugmaker Viatris to divest some of its businesses
Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Active Pharmaceutical Ingredients (API) business. It re...
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously Communicate...
Viatris and Ocuphire Pharma get FDA green light for eye treatment
Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis...
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 PITTSBURGH, and FARMINGTON HILLS, Mich. , Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global hea...
Viatris Named to TIME's World's Best Companies 2023 List
PITTSBURGH , Sept. 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list.
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
BRIDGEWATER, N.J. and BENGALURU, India, Sept.
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries PITTSBURGH and B...
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQ: VTRS) on behalf of lon...
Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug
Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its n...
Viatris beats second-quarter revenue estimates, says divestiture plans on track
Viatris Inc beat Wall Street estimates for second-quarter revenue on Monday, on the strength of its branded drug portfolio, sending its shares up 2% in premarket trading.
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Fl...
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and c...